Zacks: Allakos Inc (NASDAQ:ALLK) Given Consensus Recommendation of “Strong Buy” by Brokerages

Shares of Allakos Inc (NASDAQ:ALLK) have been given a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.

Brokerages have set a 1 year consensus price objective of $132.00 for the company and are expecting that the company will post ($0.50) earnings per share for the current quarter, according to Zacks. Zacks has also given Allakos an industry rank of 90 out of 255 based on the ratings given to related companies.

Several research firms recently weighed in on ALLK. ValuEngine cut Allakos from a “hold” rating to a “sell” rating in a research report on Wednesday, October 2nd. Zacks Investment Research cut Allakos from a “hold” rating to a “sell” rating in a research report on Tuesday.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC acquired a new position in shares of Allakos during the 3rd quarter worth about $42,000. Voya Investment Management LLC lifted its position in shares of Allakos by 14.4% during the 3rd quarter. Voya Investment Management LLC now owns 7,570 shares of the company’s stock worth $595,000 after purchasing an additional 952 shares during the last quarter. UBS Asset Management Americas Inc. lifted its position in shares of Allakos by 19.0% during the 2nd quarter. UBS Asset Management Americas Inc. now owns 6,900 shares of the company’s stock worth $299,000 after purchasing an additional 1,100 shares during the last quarter. Metropolitan Life Insurance Co NY lifted its position in shares of Allakos by 23.1% during the 3rd quarter. Metropolitan Life Insurance Co NY now owns 6,069 shares of the company’s stock worth $477,000 after purchasing an additional 1,138 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Allakos during the 3rd quarter worth about $113,000. 68.68% of the stock is owned by institutional investors and hedge funds.

Shares of NASDAQ ALLK traded down $1.40 during trading hours on Friday, hitting $82.75. 1,806 shares of the company’s stock were exchanged, compared to its average volume of 309,582. Allakos has a 1-year low of $30.32 and a 1-year high of $139.99. The stock has a market capitalization of $4.10 billion, a price-to-earnings ratio of -37.78 and a beta of -1.15. The company’s 50-day moving average price is $103.42 and its 200-day moving average price is $77.64.

Allakos (NASDAQ:ALLK) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.04). On average, research analysts predict that Allakos will post -1.88 earnings per share for the current year.

About Allakos

Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.

Read More: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on Allakos (ALLK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.